Bandwidth Inc vs Eli Lilly And Co — how do they compare? Bandwidth Inc trades at $51.42 (market cap $1.66B), while Eli Lilly And Co trades at $1,219.92 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 650.6× Bandwidth Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | LLY | |
|---|---|---|
Market Cap | $1.66B | $1.08T |
Sector | Technology | Health |
52-Week High | $78.44 | $1.24K |
52-Week Low | $12.82 | $639.43 |
Enterprise Value | $2.04B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $52.30, down 0.78% on the day, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrated solid Q2 2026 performance with EPS of $0.37 beating estimates and 22% revenue growth, driven by AI-driven communications demand and enterprise wins. Analyst sentiment remains overwhelmingly positive with 75% buy ratings and a $75.25 consensus price target representing 44% upside potential.
The outlook appears favorable with accelerating AI adoption and raised 2026 guidance, though valuation remains elevated at 34x EBITDA. Key risks include execution challenges in scaling AI deployments and competitive pressure in cloud communications. Current profitability metrics show improvement but remain thin, requiring sustained growth to justify premium multiples.
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Trailing returns across standard periods
Latest headlines on both assets
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →